Published in Nat Genet on March 17, 2013
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet (2013) 1.29
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun (2015) 1.14
Inherited genetic susceptibility to multiple myeloma. Leukemia (2013) 1.04
The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat Rev Cancer (2016) 0.98
Telomere maintenance and the etiology of adult glioma. Neuro Oncol (2015) 0.97
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun (2015) 0.92
CyclinD1, a prominent prognostic marker for endometrial diseases. Diagn Pathol (2013) 0.91
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun (2016) 0.88
DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle (2013) 0.86
Single-molecule analysis reveals widespread structural variation in multiple myeloma. Proc Natl Acad Sci U S A (2015) 0.85
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica (2015) 0.82
Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat Commun (2016) 0.81
Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol (2016) 0.81
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: Comparison to myeloma. Leukemia (2016) 0.79
Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. Leukemia (2014) 0.79
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nat Commun (2015) 0.79
Cyclin D1 splice site variant triggers chromosomal aberrations in healthy humans. Leukemia (2013) 0.79
iWAS - A novel approach to analyzing Next Generation Sequence data for immunology. Cell Immunol (2015) 0.78
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. Cancer Causes Control (2015) 0.77
Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Sci Rep (2015) 0.77
Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. Sci Rep (2016) 0.75
Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia (2015) 0.75
Search for rare protein altering variants influencing susceptibility to multiple myeloma. Oncotarget (2017) 0.75
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget (2016) 0.75
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Sci Rep (2017) 0.75
NCOA1 is a novel susceptibility gene for multiple myeloma in the Chinese population: A case-control study. PLoS One (2017) 0.75
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. Cell Rep (2017) 0.75
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
The structure of haplotype blocks in the human genome. Science (2002) 50.88
A fine-scale map of recombination rates and hotspots across the human genome. Science (2005) 26.82
Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science (2007) 23.38
Genome-wide associations of gene expression variation in humans. PLoS Genet (2005) 17.27
Common regulatory variation impacts gene expression in a cell type-dependent manner. Science (2009) 11.28
Cohort profile: 1958 British birth cohort (National Child Development Study). Int J Epidemiol (2005) 10.88
The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet (2011) 5.95
Patterns of cis regulatory variation in diverse human populations. PLoS Genet (2012) 5.28
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010) 5.04
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Data quality control in genetic case-control association studies. Nat Protoc (2010) 3.68
A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature (2011) 2.82
Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene (2006) 2.57
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood (2010) 2.33
Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol (2007) 2.14
Pathogenesis of myeloma. Annu Rev Pathol (2011) 1.91
Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annu Rev Immunol (2011) 1.75
The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet (2011) 1.69
Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia (2006) 1.69
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica (2010) 1.58
A subset-based approach improves power and interpretation for the combined analysis of genetic association studies of heterogeneous traits. Am J Hum Genet (2012) 1.57
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet (2011) 1.49
Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res (2010) 1.45
Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem (2008) 1.25
Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2008) 1.08
Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control (2010) 1.06
The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica (2012) 0.93
Alternative cyclin D1 forms a and b have different biological functions in the cell cycle of B lymphocytes. Exp Cell Res (2007) 0.89
Cyclin K and cyclin D1b are oncogenic in myeloma cells. Mol Cancer (2010) 0.88
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet (2011) 1.49
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet (2013) 1.29
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica (2015) 0.82
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A. Sci Rep (2015) 0.80
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells. Haematologica (2014) 0.79
Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. Eur J Cancer (2017) 0.76
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica (2016) 0.76
Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica (2016) 0.76
Identification of miRSNPs associated with the risk of multiple myeloma. Int J Cancer (2016) 0.75
Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells. Oncotarget (2017) 0.75
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. Haematologica (2017) 0.75